MedImmune spins out autoimmune play Viela

By Elizabeth S. Eaton | Feb 28, 2018 | 7:40 AM GMT
Editor's Note: This article was updated on Feb 28, 2018 at 11:00 PM GMT

MedImmune LLC is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of the AstraZeneca plc (LSE:AZN; NYSE:AZN) subsidiary’s Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit, will become CEO of the newco. Jorn

Read the full 444 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE